Notable Stock Movers: SCHS, PPHM, CTIC, EVC, GRPN

Houston, TX -- (SBWIRE) -- 01/09/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

School Specialty, Inc. (NASDAQ:SCHS) stock declined 29.18% to $0.740. On January 4, 2013, SCHS and certain of its wholly owned subsidiaries entered into a Forbearance Agreement relating to the Credit Agreement dated as of May 22, 2012 by and among the Company, Wells Fargo Capital Finance, LLC and General Electric Capital Corporation and GE Capital Markets, Inc., and the Lenders that are party to the Asset-Based Credit Agreement.

How Should Investors Trade SCHS After The Recent Volatile Moves? Find Out Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dropped 4.29% to $2.23 after the company yesterday provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients. The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA.

Is PPHM Showing Any Sign of Buy At The Current Market Price? Get Our Free Trend Analysis Here

Cell Therapeutics Inc (NASDAQ:CTIC) shares fell 8.60% to $1.49 after the company announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis. The randomized trial is expected to enroll 270 patients and will evaluate the safety and efficacy of pacritinib compared to best available therapy, excluding JAK inhibitors, in patients with myelofibrosis.

Is CTIC Ready To Move Back To New Highs This Year? Find Out Here

Entravision Communication (NYSE:EVC) shares climbed 7.69% to $1.82 after Wedbush upgraded Entravision two-notches from Underperform to Outperform with a price target of $2.50 (from $1.40) citing growth and an undemanding valuation.

Additionally, the company announced that Christopher T. Young , Executive Vice President, Chief Financial Officer and Treasurer, will be presenting at the 2013 Citi Global Internet, Media & Telecommunications Conference in Las Vegas at 11:15 a.m. PST on Wednesday, January 9, 2013.

Can EVC Rebound After The Recent Slump and Investors Can Make Money? Find Out Here

Groupon Inc (NASDAQ:GRPN) fell 0.10% to $5.20. Glancy Binkow & Goldberg LLP prior last week announced that it is investigating potential claims on behalf of purchasers of the common stock of Groupon, concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by Groupon between May 14, 2012 and November 8, 2012 were false and misleading concerning the Company's business and financial prospects.

How Should Investors Trade GRPN After The Recent Volatile Moves? Find Out Here

Disclaimer
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information
Winning Media LLC
1-800-411-7716
ir@AnotherWinningTrade.com